Your session is about to expire
← Back to Search
Trametinib for Solid Tumors
Study Summary
This trial is testing the side effects and best dose of two drugs, trametinib and navitoclax, for treating patients with advanced or metastatic solid tumors. Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth, and navitoclax may stop the growth of cancer cells by blocking proteins needed for cancer cell survival.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2021 Phase 2 trial • 206 Patients • NCT02034110Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are we able to sign up for the trial at this time?
"This study is not seeking patients at the moment. According to the latest update on 11/8/2022, this trial was initially posted on 3/7/2014. If you're interested in other studies, there are 2467 trials for malignant neoplasms and 107 Trametinib studies that are still enrolling patients."
What other research exists in this area?
"Trametinib has been researched since 2009. The very first study was conducted in 2009 and was sponsored by AbbVie (prior sponsor, Abbott). Following the first trial in 2009, which involved 29 patients, Trametinib received its Phase 1 drug approval. Today there are 107 live studied for Trametinib across 1298 cities and 45 countries."
What are the main goals that researchers hope to achieve with this trial?
"The goal of this study is to assess progression-free survival over a period of up to 30 days. Secondary outcomes include response rate (partial response + complete response) and pharmacokinetic parameters for trametinib and navitoclax when administered in combination. Results will be reported as a percent (%) increase or decrease in level of a given marker after treatment initiation (post treatment biopsy) relative to before treatment (pre-treatment biopsy)."
Are there other instances where Trametinib has been used in research?
"Out of the 107 ongoing Trametinib studies, 8 have reached Phase 3. The high number of trials for this treatment is due in part to the popularity of the medication. Duarte, California serves as the headquarters for many of these clinical trials; however, there are 6580 total locations running Trametinib trials."
How many test subjects are needed for this research?
"This research is not currently looking for new participants. The earliest posting was on March 7th, 2014 with the most recent update being November 8th, 2029. There are 2467 other studies actively recruiting patients for malignant neoplasms and 107 clinical trials involving Trametinib that are still enrolling individuals."
Share this study with friends
Copy Link
Messenger